Predictive value of the stress hyperglycemia ratio in patients with acute ST-segment elevation myocardial infarction: insights from a multi-center observational study.
Diabetes mellitus
ST-segment elevation myocardial infarction
Stress hyperglycemia ratio
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
29 03 2022
29 03 2022
Historique:
received:
21
01
2022
accepted:
09
03
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
6
4
2022
Statut:
epublish
Résumé
Stress hyperglycemia is a strong predictor of adverse outcomes in patients with acute myocardial infarction (AMI). Recently, the stress hyperglycemia ratio (SHR) has been designed as an index to identify acute hyperglycemia with true risk; however, data regarding the impact of SHR on the prognosis of ST-segment elevation myocardial infarction (STEMI) remains limited. This study aimed to evaluate the predictive value of the SHR in patients with acute STEMI and to assess whether it can improve the predictive efficiency of the Thrombolysis in Myocardial Infarction (TIMI) risk score. This study included 7476 consecutive patients diagnosed with acute STEMI across 274 emergency centers. After excluding 2052 patients due to incomplete data, 5417 patients were included in the final analysis. Patients were divided into three groups according to SHR tertiles (SHR1, SHR2, and SHR3) and were further categorized based on diabetes status. All patients were followed up for major cardiovascular adverse events (MACEs) and all-cause mortality. After 30 days of follow-up, 1547 MACEs (28.6%) and 789 all-cause deaths (14.6%) occurred. The incidence of MACEs was highest among patients in the SHR3 group with diabetes mellitus (DM) (42.6%). Kaplan-Meier curves demonstrated that patients with SHR3 and DM also had the highest risk for MACEs when compared with other groups (p < 0.001). Moreover, C-statistics improved significantly when SHR3 was added into the original model: the ΔC-statistics (95% confidence interval) were 0.008 (0.000-0.013) in the total population, 0.010 (0.003-0.017) in the DM group, and 0.007 (0.002-0.013) in the non-DM group (all p < 0.05). In the receiver operating characteristic analysis, the area under the curve (AUC) for the original TIMI risk score for all-cause death was 0.760. When an SHR3 value of 1 point was used to replace the history of DM, hypertension, or angina in the original TIMI risk score, the Delong test revealed significant improvements in the AUC value (∆AUC of 0.009, p < 0.05), especially in the DM group (∆AUC of 0.010, p < 0.05). The current results suggest that SHR is independently related to the risks of MACEs and mortality in patients with STEMI. Furthermore, SHR may aid in improving the predictive efficiency of the TIMI risk score in patients with STEMI, especially those with DM.
Sections du résumé
BACKGROUND
Stress hyperglycemia is a strong predictor of adverse outcomes in patients with acute myocardial infarction (AMI). Recently, the stress hyperglycemia ratio (SHR) has been designed as an index to identify acute hyperglycemia with true risk; however, data regarding the impact of SHR on the prognosis of ST-segment elevation myocardial infarction (STEMI) remains limited. This study aimed to evaluate the predictive value of the SHR in patients with acute STEMI and to assess whether it can improve the predictive efficiency of the Thrombolysis in Myocardial Infarction (TIMI) risk score.
METHODS
This study included 7476 consecutive patients diagnosed with acute STEMI across 274 emergency centers. After excluding 2052 patients due to incomplete data, 5417 patients were included in the final analysis. Patients were divided into three groups according to SHR tertiles (SHR1, SHR2, and SHR3) and were further categorized based on diabetes status. All patients were followed up for major cardiovascular adverse events (MACEs) and all-cause mortality.
RESULTS
After 30 days of follow-up, 1547 MACEs (28.6%) and 789 all-cause deaths (14.6%) occurred. The incidence of MACEs was highest among patients in the SHR3 group with diabetes mellitus (DM) (42.6%). Kaplan-Meier curves demonstrated that patients with SHR3 and DM also had the highest risk for MACEs when compared with other groups (p < 0.001). Moreover, C-statistics improved significantly when SHR3 was added into the original model: the ΔC-statistics (95% confidence interval) were 0.008 (0.000-0.013) in the total population, 0.010 (0.003-0.017) in the DM group, and 0.007 (0.002-0.013) in the non-DM group (all p < 0.05). In the receiver operating characteristic analysis, the area under the curve (AUC) for the original TIMI risk score for all-cause death was 0.760. When an SHR3 value of 1 point was used to replace the history of DM, hypertension, or angina in the original TIMI risk score, the Delong test revealed significant improvements in the AUC value (∆AUC of 0.009, p < 0.05), especially in the DM group (∆AUC of 0.010, p < 0.05).
CONCLUSION
The current results suggest that SHR is independently related to the risks of MACEs and mortality in patients with STEMI. Furthermore, SHR may aid in improving the predictive efficiency of the TIMI risk score in patients with STEMI, especially those with DM.
Identifiants
pubmed: 35351149
doi: 10.1186/s12933-022-01479-8
pii: 10.1186/s12933-022-01479-8
pmc: PMC8962934
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Informations de copyright
© 2022. The Author(s).
Références
Circulation. 2000 Oct 24;102(17):2031-7
pubmed: 11044416
Kardiol Pol. 2021 Feb 25;79(2):170-178
pubmed: 33394580
Lancet. 2000 Mar 4;355(9206):773-8
pubmed: 10711923
Crit Care. 2013 Mar 06;17(2):305
pubmed: 23470218
J Clin Endocrinol Metab. 2015 Dec;100(12):4490-7
pubmed: 26485219
Angiology. 2020 Jan;71(1):38-47
pubmed: 31554413
Diab Vasc Dis Res. 2020 Jan-Feb;17(1):1479164119883983
pubmed: 31726871
Int J Cardiol. 2013 Sep 10;167(6):2572-9
pubmed: 22795245
J Am Coll Cardiol. 2000 Sep;36(3):959-69
pubmed: 10987628
Mol Metab. 2021 Sep;51:101246
pubmed: 33964506
Diabetologia. 2020 Oct;63(10):2102-2111
pubmed: 32647915
Front Cardiovasc Med. 2021 Jul 20;8:698725
pubmed: 34355031
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Clin Endocrinol Metab. 2002 Dec;87(12):5516-23
pubmed: 12466347
Cardiovasc Diabetol. 2021 Sep 24;20(1):192
pubmed: 34560876
Cardiovasc Diabetol. 2017 Dec 12;16(1):157
pubmed: 29233143
Diabetes Care. 2018 Apr;41(4):847-853
pubmed: 29382659
Eur Heart J. 2014 Aug 1;35(29):1957-70
pubmed: 24419804
Clin Res Cardiol. 2011 Aug;100(8):649-59
pubmed: 21347741
Lancet. 2009 May 23;373(9677):1798-807
pubmed: 19465235
Crit Care Med. 2009 Oct;37(10):2856-8
pubmed: 19865018
J Clin Endocrinol Metab. 2004 Nov;89(11):5382-6
pubmed: 15531485
Int J Cardiol. 2017 Aug 15;241:57-63
pubmed: 28256326
Metabolism. 2021 Oct;123:154845
pubmed: 34364927
Cardiovasc Diabetol. 2021 Oct 19;20(1):211
pubmed: 34666746